Publicacions en què col·labora amb B. Pérez Valderrama (6)

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2018

  1. Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (57-68), 10.1007/s12094-017-1783-2)

    Clinical and Translational Oncology

  2. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 57-68

2015

  1. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 96, Núm. 2, pp. 308-318

2014

  1. Denosumab: Treatment efficacy in the control of metastatic bone disease

    Cancer and Chemotherapy Reviews, Vol. 9, Núm. 1, pp. 27-32

2012

  1. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 83, Núm. 3, pp. 341-352